Pulmonary vascular disease in bronchopulmonary dysplasia: Pulmonary hypertension and beyond

Current Opinion in Pediatrics

Volumn 25, Issue 3, 2013, Pages 329-337

  Mourani, Peter M ^a   Abman, Steven H ^a  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

Bronchopulmonary dysplasia; Chronic lung disease of infancy; Echocardiogram; Phosphodiesterase inhibitors; Pulmonary hypertension

Indexed keywords

ENDOTHELIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; SILDENAFIL; VASCULOTROPIN;

CHRONIC LUNG DISEASE; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HIGH RISK PATIENT; HUMAN; LUNG CIRCULATION; LUNG DEVELOPMENT; LUNG DYSPLASIA; NONHUMAN; PATHOGENESIS; PREMATURITY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

ANTIHYPERTENSIVE AGENTS; BRONCHOPULMONARY DYSPLASIA; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; INFANT, PREMATURE; PERIPHERAL VASCULAR DISEASES;

EID: 84879902542     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328360a3f6     Document Type: Review

References (93)

1. Smith VC, Zupancic JA, McCormick MC, et al. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr 2005; 146:469-473.
2. Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126:443-456.
3. Husain AN, Siddiqui NH, Stocker JT. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Hum Pathol 1998; 29:710-717.
4. Coalson JJ. Pathology of chronic Lung Disease in Infancy. In: Bland RD, Coalson JJ, editors. Chronic Lung Disease of Early Infancy. New York: Marcel Dekker; 2000. pp. 85-124.
5. Bancalari E, Gonzalez A. Clinical course and lung function abnormalities during development of neonatal chronic lung disease. In: Bland R, Coalson J, editors. Chronic lung disease in early infancy. New York: Marcel Dekker; 2000. pp. 41-64.
6. Charafeddine L, D'Angio CT, Phelps DL. Atypical chronic lung disease patterns in neonates. Pediatrics 1999; 103:759-765.
7. Coalson JJ. Pathology of new bronchopulmonary dysplasia. Semin Neonatol 2003; 8:73-81.
8. Mourani PM, Abman SH. Pulmonary Vascular Disease in Bronchopulmonary Dysplasia: Physiology, Diagnosis, and Treatment. In: Abman SH, editor. Bronchopulmonary Dysplasia. New York: Informa Healthcare; 2010. pp. 347-363.
9. Hislop AA, Haworth SG. Pulmonary vascular damage and the development of cor pulmonale following hyaline membrane disease. Pediatr Pulmonol 1990; 9:152-161.
10. Abman SH. Bronchopulmonary dysplasia: 'a vascular hypothesis'. Am J Respir Crit Care Med 2001; 164:1755-1756.
11. Abman SH. The dysmorphic pulmonary circulation in bronchopulmonary dysplasia: a growing story. Am J Respir Crit Care Med 2008; 178:114-115.
12. Jobe AH. An unknown: lung growth and development after very preterm birth. Am J Respir Crit Care Med 2002; 166:1529-1530.
13. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009; 154:379-384; e372.
14. Mourani PM, Sontag MK, Younoszai A, et al. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 2008; 121:317-325.
15. An HS, Bae EJ, Kim GB, et al. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Korean Circ J 2010; 40:131-136.
16. Bhat R, Salas AA, Foster C, et al. Prospective analysis of pulmonary hypertension in extremely low birth weight infants. Pediatrics 2012; 129:e682-e689.
17. Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007; 120:1260-1269.
18. Gorenflo M, Vogel M, Obladen M. Pulmonary vascular changes in bronchopulmonary dysplasia: a clinicopathologic correlation in short- and long-term survivors. Pediatr Pathol 1991; 11:851-866.
19. Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res 1999; 46:641-643.
20. Bush A, Busst CM, Knight WB, et al. Changes in pulmonary circulation in severe bronchopulmonary dysplasia. Arch Dis Child 1990; 65:739-745.
21. Hislop AA, Wigglesworth JS, Desai R, Aber V. The effects of preterm delivery and mechanical ventilation on human lung growth. Early Hum Dev 1987; 15:147-164.
22. Abman SH. Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. Adv Exp Med Biol 2010; 661:323-335.
23. Cornfield DN. Developmental regulation of oxygen sensing and ion channels in the pulmonary vasculature. Adv Exp Med Biol 2010; 661:201-220.
24. D'Angio CT, Maniscalco WM. The role of vascular growth factors in hyperoxia-induced injury to the developing lung. Front Biosci 2002; 7:d1609-d1623.
25. Kumar VH, Ryan RM. Growth factors in the fetal and neonatal lung. Front Biosci 2004; 9:464-480.
26. Lassus P, Turanlahti M, Heikkila P, et al. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med 2001; 164:1981-1987.
27. Thebaud B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med 2007; 175:978-985.
28. Maniscalco WM, Watkins RH, Pryhuber GS, et al. Angiogenic factors and alveolar vasculature: development and alterations by injury in very premature baboons. Am J Physiol Lung Cell Mol Physiol 2002; 282:L811-L823.
29. Bhandari V, Bizzarro MJ, Shetty A, et al. Familial and genetic susceptibility to major neonatal morbidities in preterm twins. Pediatrics 2006; 117:1901-1906.
30. Bhandari V, Gruen JR. The genetics of bronchopulmonary dysplasia. Semin Perinatol 2006; 30:185-191.
31. Jakkula M, Le Cras TD, Gebb S, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2000; 279:L600-L607.
32. Stenmark KR, Abman SH. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol 2005; 67:623-661.
33. Yamamoto H, Yun EJ, Gerber HP, et al. Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis. Dev Biol 2007; 308:44-53.
34. Hansen AR, Barnes CM, Folkman J, McElrath TF. Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr 2010; 156:532-536.
35. Foidart JM, Schaaps JP, Chantraine F, et al. Dysregulation of antiangiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia-a step forward but not the definitive answer. J Reprod Immunol 2009; 82:106-111.
36. Lapaire O, Shennan A, Stepan H. The preeclampsia biomarkers soluble fmslike tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. Eur J Obstet Gynecol Reprod Biol 2010; 151:122-129.
37. Tang JR, Karumanchi SA, Seedorf G, et al. Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2012; 302:L36-L46.
38. Li F, Hagaman JR, Kim HS, et al. eNOS deficiency acts through endothelin to aggravate sFlt-1-induced preeclampsia-like phenotype. J Am Soc Nephrol 2012; 23:652-660.
39. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001; 26:25-35.
40. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992-1005.
41. Wang CN, Chang SD, Peng HH, et al. Change in amniotic fluid levels of multiple antiangiogenic proteins before development of preeclampsia and intrauterine growth restriction. J Clin Endocrinol Metab 2010; 95:1431-1441.
42. Check J, Gotteiner N, Liu X, et al. Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia. J Perinatol 2013. [Epub ahead of print]
43. Rozance PJ, Seedorf GJ, Brown A, et al. Intrauterine growth restriction decreases pulmonary alveolar and vessel growth and causes pulmonary artery endothelial cell dysfunction in vitro in fetal sheep. Am J Physiol Lung Cell Mol Physiol 2011; 301:L860-871.
44. Thebaud B, Ladha F, Michelakis ED, et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation 2005; 112:2477-2486.
45. Galambos C, Ng YS, Ali A, et al. Defective pulmonary development in the absence of heparin-binding vascular endothelial growth factor isoforms. Am J Respir Cell Mol Biol 2002; 27:194-203.
46. De Paepe ME, Mao Q, Powell J, et al. Growth of pulmonary microvasculature in ventilated preterm infants. Am J Respir Crit Care Med 2006; 173:204-211.
47. Janer J, Andersson S, Kajantie E, Lassus P. Endostatin concentration in cord plasma predicts the development of bronchopulmonary dysplasia in very low birth weight infants. Pediatrics 2009; 123:1142-1146.
48. Mitchell SH, Teague WG. Reduced gas transfer at rest and during exercise in school-age survivors of bronchopulmonary dysplasia. Am J Respir Crit Care Med 1998; 157:1406-1412.
49. Hakulinen AL, Jarvenpaa AL, Turpeinen M, Sovijarvi A. Diffusing capacity of the lung in school-aged children born very preterm, with and without bronchopulmonary dysplasia. Pediatr Pulmonol 1996; 21:353-360.
50. Allen J, Zwerdling R, Ehrenkranz R, et al. Statement on the care of the child with chronic lung disease of infancy and childhood. Am J Respir Crit Care Med 2003; 168:356-396.
51. Grover TR, Parker TA, Balasubramaniam V, et al. Pulmonary hypertension impairs alveolarization and reduces lung growth in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2005; 288:L648-654.
52. Gien J, Tseng N, Seedorf G, et al. Endothelin-1 impairs angiogenesis in vitro through Rho-kinase activation after chronic intrauterine pulmonary hypertension in fetal sheep. Pediatr Res 2013; 73:252-262.
53. van Haaften T, Byrne R, Bonnet S, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med 2009; 180:1131-1142.
54. O'Reilly M, Thebaud B. Cell-based strategies to reconstitute lung function in infants with severe bronchopulmonary dysplasia. Clin Perinatol 2012; 39:703-725.
55. Irwin D, Helm K, Campbell N, et al. Neonatal lung side population cells demonstrate endothelial potential and are altered in response to hyperoxiainduced lung simplification. Am J Physiol Lung Cell Mol Physiol 2007; 293:L941-L951.
56. Balasubramaniam V, Mervis CF, Maxey AM, et al. Hyperoxia reduces bone marrow, circulating, and lung endothelial progenitor cells in the developing lung: implications for the pathogenesis of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2007; 292:L1073-L1084.
57. Baker CD, Balasubramaniam V, Mourani PM, et al. Cord blood angiogenic progenitor cells are decreased in bronchopulmonary dysplasia. Eur Respir J 2012; 40:1516-1522.
58. Borghesi A, Massa M, Campanelli R, et al. Circulating endothelial progenitor cells in preterm infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2009; 180:540-546.
59. Paviotti G, Fadini GP, Boscaro E, et al. Endothelial progenitor cells, bronchopulmonary dysplasia and other short-term outcomes of extremely preterm birth. Early Hum Dev 2011; 87:461-465.
60. Popova AP, Bozyk PD, Bentley JK, et al. Isolation of tracheal aspirate mesenchymal stromal cells predicts bronchopulmonary dysplasia. Pediatrics 2010; 126:e1127-e1133.
61. Popova AP, Bozyk PD, Goldsmith AM, et al. Autocrine production of TGFbeta1 promotes myofibroblastic differentiation of neonatal lung mesenchymal stem cells. Am J Physiol Lung Cell Mol Physiol 2010; 298:L735-743.
62. Pierro M, Thebaud B. Mesenchymal stem cells in chronic lung disease: culprit or savior? Am J Physiol Lung Cell Mol Physiol 2010; 298:L732-L734.
63. Tropea KA, Leder E, Aslam M, et al. Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2012; 302:L829-837.
64. Zhang X, Wang H, Shi Y, et al. Role of bone marrow-derived mesenchymal stem cells in the prevention of hyperoxia-induced lung injury in newborn mice. Cell Biol Int 2012; 36:589-594.
65. Chang YS, Choi SJ, Sung DK, et al. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells dose-dependently attenuates hyperoxia-induced lung injury in neonatal rats. Cell Transplant 2011; 20:1843-1854.
66. Balasubramaniam V, Ryan SL, Seedorf GJ, et al. Bone marrow-derived angiogenic cells restore lung alveolar and vascular structure after neonatal hyperoxia in infant mice. Am J Physiol Lung Cell Mol Physiol 2010; 298:L315-L323.
67. De Paepe ME, Hanley LC, Lacourse Z, et al. Pulmonary dendritic cells in lungs of preterm infants: neglected participants in bronchopulmonary dysplasia? Pediatr Dev Pathol 2011; 14:20-27.
68. Iosef C, Alastalo TP, Hou Y, et al. Inhibiting NF-kappaB in the developing lung disrupts angiogenesis and alveolarization. Am J Physiol Lung Cell Mol Physiol 2012; 302:L1023-1036.
69. Roberts RJ, Weesner KM, Bucher JR. Oxygen-induced alterations in lung vascular development in the newborn rat. Pediatr Res 1983; 17:368-375.
70. Nozik-Grayck E, Stenmark KR. Role of reactive oxygen species in chronic hypoxia-induced pulmonary hypertension and vascular remodeling. Adv Exp Med Biol 2007; 618:101-112.
71. Jones R, Zapol WM, Reid L. Pulmonary artery remodeling and pulmonary hypertension after exposure to hyperoxia for 7 days. A morphometric and hemodynamic study. Am J Pathol 1984; 117:273-285.
72. Yee M, White RJ, Awad HA, et al. Neonatal hyperoxia causes pulmonary vascular disease and shortens life span in aging mice. Am J Pathol 2011; 178:2601-2610.
73. Wong PM, Lees AN, Louw J, et al. Emphysema in young adult survivors of moderate-to-severe bronchopulmonary dysplasia. Eur Respir J 2008; 32: 321-328.
74. Balinotti JE, Chakr VC, Tiller C, et al. Growth of lung parenchyma in infants and toddlers with chronic lung disease of infancy. Am J Respir Crit Care Med 2010; 181:1093-1097.
75. Lum S, Kirkby J, Welsh L, et al. Nature and severity of lung function abnormalities in extremely preterm children at 11 years of age. Eur Respir J 2011; 37:1199-1207.
76. Walther FJ, Benders MJ, Leighton JO. Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome. Pediatrics 1992; 90:899-904.
77. Fouron JC, Le Guennec JC, Villemant D, et al. Value of echocardiography in assessing the outcome of bronchopulmonary dysplasia of the newborn. Pediatrics 1980; 65:529-535.
78. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70:657-662.
79. Berger M, Haimowitz A, Van Tosh A, et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985; 6:359-365.
80. Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler- catheterization study in 127 patients. J Am Coll Cardiol 1985; 6:750-756.
81. Skjaerpe T, Hatle L. Noninvasive estimation of systolic pressure in the right ventricle in patients with tricuspid regurgitation. Eur Heart J 1986; 7:704-710.
82. Slaughter JL, Pakrashi T, Jones DE, et al. Echocardiographic detection of pulmonary hypertension in extremely low birth weight infants with bronchopulmonary dysplasia requiring prolonged positive pressure ventilation. J Perinatol 2011; 31:635-640.
83. Benatar A, Clarke J, Silverman M. Pulmonary hypertension in infants with chronic lung disease: noninvasive evaluation and short term effect of oxygen treatment. Arch Dis Child Fetal Neonatal Ed 1995; 72:F14-F19.
84. Kim DH, Kim HS, Choi CW, et al. Risk factors for pulmonary artery hypertension in preterm infants with moderate or severe bronchopulmonary dysplasia. Neonatology 2012; 101:40-46.
85. Czernik C, Rhode S, Metze B, et al. Persistently elevated right ventricular index of myocardial performance in preterm infants with incipient bronchopulmonary dysplasia. PLoS One 2012; 7:e38352.
86. Kobr J, Fremuth J, Pizingerova K, et al. Repeated bedside echocardiography in children with respiratory failure. Cardiovasc Ultrasound 2011; 9:14.
87. Nyp M, Sandritter T, Poppinga N, et al. Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits? J Perinatol 2012; 32:64-69.
88. Drossner DM, Kim DW, Maher KO, Mahle WT. Pulmonary vein stenosis: prematurity and associated conditions. Pediatrics 2008; 122:e656-e661.
89. Mourani PM, Ivy DD, Rosenberg AA, et al. Left ventricular diastolic dysfunction in bronchopulmonary dysplasia. J Pediatr 2008; 152:291-293.
90. Mourani PM, Mullen M, Abman SH. Pulmonary hypertension in bronchopulmonary dysplasia. Prog Pediatr Cardiol 2009; 27:43-48.
91. Robbins IM, Moore TM, Blaisdell CJ, Abman SH. Improving outcomes for pulmonary vascular disease. Am J Respir Crit Care Med 2012; 185:1015-1020.
92. Abman SH, Kinsella JP, Rosenzweig EB, et al. Implications of the FDA warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Am J Respir Crit Care Med 2013; 187:572-575.
93. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebocontrolled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012; 125:324-334.